The purpose of this study is to compare the radiation therapy (RT) and radical prostatectomy (RP) of high-risk or locally advanced prostate cancer (PC) patients after neoadjuvant hormonal therapy (NHT).
INTRODUCTION
Prostate cancer (PC) is the most prevalent cancer and the second leading cause of cancer-related death among men. 1 Thus, PC is associated with a major health burden and its heterogeneity produces diverse clinical outcomes, which makes it difficult to identify patients with high risks of recurrence and progression. Thus, stratifying patients into low-, intermediate-,
and high-risk (or very high risk) groups based on different risk factors have been suggested (e.g., based on their initial pros-tate-specific antigen [PSA] level, Gleason score, or disease stage). 2, 3 According to version 3.2016 of the National Comprehensive
Cancer Network guidelines for PC, a high risk of PC is considered present for patients with PSA levels of ≥20 ng/mL, Gleason scores of ≥8, or clinical T3 tumors. 3 The treatment options for high-risk PC include external beam radiation therapy (RT) plus androgen-deprivation therapy (ADT) with/without brachytherapy or radical prostatectomy plus pelvic lymph nodal dissection (RP). Both RT and RP provide similar local control rates and improve survival and quality of life. 4, 5 Neoadjuvant hormonal therapy (NHT) can help improve recurrence-free survival among men with advanced PC who receive ADT and RP. 6 This is because NHT reduces the tumor's size, improves surgical curability by inhibiting the growth of PC cells, and promotes down-staging, lower regional metastasis rates, better organ confinement, and decreased lymph node involvement. 7 However, these effects do not translate into better overall survival (OS) or disease-free survival. 6 Nevertheless, among localized high-risk or locally advanced PC cases, the time to biochemical recurrence (BCR) after NHT (i.e., the time from the PSA nadir after treatment) can influence the long-term BCR-free outcomes after RT among patients with PC.
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No large-scale prospective randomized clinical trials have compared the existing treatment options with NHT, and there are no optimal management strategies for patients with high-risk PC. Moreover, previous studies comparing RP and RT are difficult to interpret, because of the presence of comorbidities, biased treatment selection criteria, incomplete follow-up data, varied treatment protocols, and reliance on surrogate endpoints. 9 Therefore, we aimed to compare RT and RP for patients with high-risk PC after NHT using various outcomes:
BCR-free survival (BCRFS), pelvic local recurrence-free survival (PLRFS), metastasis-free survival (MFS), clinical pain-free survival (CPFS), castration-resistant PC (CRPC), and OS. The planning target volume was defined using a safety margin of 10 mm in most directions, with a posterior margin of 6 mm.
MATERIALS AND METHODS
The total radiation dose was 70-76 Gy delivered in 2-Gy fractions five times per week. The pain scale and the pain description including narcotic analgesics were reviewed retrospectively from the medical charts to evaluate the grade of pain scale from pain-specialized anesthesiologists and clinicians.
These outcomes were generally calculated from the surgery for the RP group and from the end of RT for the RT group.
However, if the period between NHT and adjuvant HT was ＜1 month in the RT group, the time to BCR was calculated from the start of RT, rather than from the end of RT. The last follow-up was used to calculate the duration for censored events.
Survival curves were plotted using the Kaplan-Meier method and compared using the log-rank test. Multivariable Cox pro- 
RESULTS
During a median follow-up of 71.7 months (range, 1.4-155.0 months), the 3-and 5-year OS rates were 91.5% and 78.6%
for RT, compared to 94.3% and 90.1% for RP without reaching the median OS (Fig. 1) (Fig. 2) . 
DISCUSSION
Global reports have indicated that ＜20% of patients with newly diagnosed PC have locally advanced or localized highrisk PC (i.e., T3 stage), 13, 14 in which the tumor has spread beyond the prostatic capsule or grown into the seminal vesicles. Fig. 2 ). It is possible that this difference is related to the time needed to reach the nadir PSA level in the two groups, as the nadir PSA level may not be observed for 1-2 years (occasionally longer) among patients receiving RT. In contrast, almost all RP-treated patients will achieve the nadir PSA level within 1-2 months after treatment. Thus, clinically meaningful and reliable results may require longer follow-up periods than the follow-up for the present study. The RT group experienced significantly inferior CPFS (p=0.013) ( Table 2 , Fig. 2 ). In this context, bowel and bladder complications are common after RT, especially among patients who are treated using 3D-CRT (vs. intensity-modulated RT).
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Furthermore, Cicchetti et al. 24 reported pooled results from the Airopros 0102 and TROG03.04 RADAR trials, which involved prescribed 3D-CRT doses (66-80 Gy; median, 73.2 Gy; interquartile range, 70-75 Gy; 1.8-2 Gy/day) that were comparable to the present study's prescribed doses (70-76 Gy, 2 Gy/day).
In those trials, large rectal volumes that received mid-range doses (30-50 Gy) were associated with rectal pain. Thus, Cicchetti et al. 24 concluded that sparing the anorectal area from low-to-mid-range doses may reduce the incidence of rectal pain.
This may explain why the present study detected better CPFS in the RP group, compared to the RT group.
The RT group always underwent HT before and after RT, whereas NHT is typically used as a standard therapy without surgery. Nevertheless, it is difficult to surgically remove high-risk PC tumors with negative margins, given the large tumor burden, and NHT may help reduce the prostate's size and control the surgical margins. For example, several studies have indicated that NHT before RP reduced the rate of positive surgical margins, which potentially resulted in complete pathological responses. 25 However, differences in the 2 groups' characteristics (e.g., physical condition, staging, and hormonal duration and agent) make it difficult to compare these outcomes, despite significant differences being observed for BCR and CPFS (Fig. 2) . Moreover, NHT has not been confirmed to be beneficial for patient outcomes, especially in terms of PSA-free survival in randomized trials. 26 Among patients with high-risk PC, the reported rates of PSA-free survival after RP alone were 35%-62%, which are similar to the rate from the present study.
In addition, a systematic review of adjuvant HT plus NHT with RP or RT for high risk or locally advanced PC revealed that NHT before RP did not significantly improve OS (odds ratio, 1.11; p=0.69). 27 Nevertheless, it did provide significant improvements in the positive surgical margin rate, lymph node involvement, pathological staging, and organ confinement (all p＜ 0.05). However, the outcomes were not significantly different between RP and RT after NHT, with the exception of significantly better CPFS in the RP group.
Other systematic reviews have revealed significant hetero- Thus, additional research is needed regarding HT choice, duration, and scheduling, which should consider the long-term effects of patient's quality of life and potential toxicity.
In our study, the RT group showed better 5-year OS rate than the RP group. The authors presume that the reason for this is due to the fact that the number of RP group was higher and the FU duration was longer than RT group. As a result, patients who became censored were more likely to have RP group than RT group. However, the number of deaths of RP group is lower than RT group. Therefore, if the FU duration becomes longer and the number of patients increases, the OS rate may change.
In addition, significant downstaging (pT3N0+pT4N0=2.03%) and a positive surgical margin (PSM) rate of 4.6% were demonstrated in the neoadjuvant HT before the RP group, as shown in Table 1 . In one previous study, 29 56% of pT3-4 and 49%
of PSM rate were reported in RP without neoadjuvant HT.
The present study has several limitations. First, the retrospective design and small sample size are associated with risks of selection bias. Those patients received RT and transferred to other hospitals for the follow-up were excluded at the early enrollment. Second, the RP group had received NHT, while the RT group had received NHT and adjuvant HT. Third, the study was not able to evaluate data regarding health-related quality of life (e.g., continence and erectile function), which could affect treatment selection. Nevertheless, the present study's results may help improve the management of patients with high-risk PC, based on the lack of prospective randomized clinical trials.
CONCLUSIONS
The present study revealed that, among patients with highrisk PC previously treated using NHT, the RP group experienced better CPFS than the RT group after adjusting for clinical TN stage.
